Study on Liraglutide and Behavioral Therapy for Weight Loss

Background on Obesity in the United States

Obesity is a prevalent issue in the United States, affecting nearly 40 percent of American adults as of 2015. This condition heightens the risk of various chronic diseases, including heart disease, type 2 diabetes, and certain cancers. Additionally, individuals with obesity often face negative societal perceptions and comments regarding their body size.

Need for Effective Weight Loss Strategies

With numerous diets and programs available, not all have proven effective for weight loss. Researchers continue to explore optimal strategies to combat the high obesity rates in the U.S. Two promising approaches include liraglutide, a medication used to manage blood sugar levels in type 2 diabetes patients, and intensive behavioral therapy.

Study Overview

A recent study published in the journal *Obesity* investigated the combined effects of liraglutide and intensive behavioral therapy on weight loss among obese patients. The study involved 282 obese adults from 17 clinics across the United States.

Study Design and Results

Participants were divided into two groups. The control group consisted of 140 individuals who received a placebo along with 23 15-minute sessions of intensive behavioral therapy over 56 weeks. The experimental group included 142 participants who were administered 3.0 milligrams of liraglutide alongside the same behavioral therapy for the same duration.

At the conclusion of the study, 61.5 percent of the experimental group achieved clinically meaningful weight loss, compared to 38.8 percent in the control group. Clinically meaningful weight loss is defined as a reduction of five percent or more of initial body mass. The experimental group experienced an average weight loss of 7.4 percent, while the control group lost an average of 4.0 percent. Furthermore, both groups that achieved clinically meaningful weight loss showed reductions in waist circumference, triglyceride levels, and improvements in quality of life.

Conclusions and Future Research

The findings from this study indicate that the combination of intensive behavioral therapy and liraglutide may be an effective strategy for facilitating clinically meaningful weight loss in obese individuals. Additionally, the results suggest that intensive behavioral therapy alone may also yield positive outcomes, as many participants in the control group experienced weight loss. Further research is necessary to fully understand the effectiveness of these weight loss strategies.

References

– Adult Obesity Facts. (2018, August 13). Retrieved February 24, 2020, from https://www.cdc.gov/obesity/data/adult.html
– Doheny, K. (2015, August 31). Diabetes Drug Liraglutide Shows Promising Weight Loss Benefit. Retrieved February 24, 2020, from https://www.endocrineweb.com/news/diabetes/16461-diabetes-drug-liraglutide-shows-promising-weight-loss-benefit
– Intensive behavioral therapy and liraglutide 3.0 mg show positive results for weight loss. (2020, February 24). Retrieved February 24, 2020, from https://www.eurekalert.org/pub_releases/2020-02/tos-ibt021820.php
– Wadden, T. A., Shaw Tronieri, J., Sugimoto, D., Taulo Lund, M., Auerbach, P., Jensen, C., & Rubino, D. (2020). Liraglutide 3.0mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. *Obesity*, 28(3). doi: 10.1002/oby.22726